Design Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The unaudited filing was submitted May 8, 2024.
Business context
Design Therapeutics is a pre-revenue biopharmaceutical company developing GeneTAC small-molecule candidates for inherited nucleotide repeat expansion diseases. Its programs target Friedreich ataxia (FA), Fuchs endothelial corneal dystrophy (FECD), Huntington’s disease (HD), and myotonic dystrophy type 1 (DM1). No product candidates are approved for sale.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Product revenue | None reported | None reported |
| Research and development expense | $9.8 million | $15.7 million; down $5.9 million |
| General and administrative expense | $4.6 million | $5.9 million; down $1.3 million |
| Total operating expenses | $14.4 million | $21.7 million; down $7.3 million |
| Other income, net | $3.3 million | $2.4 million |
| Net loss | $11.1 million | $19.3 million |
| Net loss per share | $0.20 | $0.35 |
| Cash used in operating activities | $12.4 million | $17.4 million |
| Cash, cash equivalents and investments | $270.7 million at March 31, 2024 | $281.8 million at December 31, 2023 |
The R&D decline primarily reflected lower FA clinical activity and lower spending on early-stage programs; FECD direct R&D spending began in the comparative table at $1.2 million. G&A fell mainly because of lower personnel-related costs and professional fees. The company reported no product revenue, so product margins are not applicable. It reported no debt; liabilities primarily included operating lease obligations, including $2.9 million in total lease liabilities. Accumulated deficit was $188.7 million.
Cash and cash equivalents were $29.4 million and investment securities were $241.3 million at quarter-end. Management expects available resources to fund anticipated requirements for more than 12 months following issuance of the financial statements, but states that substantial additional financing will be needed to develop and potentially commercialize candidates.
Material changes and operating developments
- DT-216, the earlier FA formulation, produced FXN mRNA increases in Phase 1 studies but was associated with injection-site thrombophlebitis. The company withdrew that candidate’s IND in October 2023 and is advancing DT-216P2, a reformulated candidate using the same drug substance.
- The company reported higher and more sustained exposure and favorable injection-site tolerability for DT-216P2 in nonclinical work. These findings are preliminary and do not establish clinical safety or efficacy.
- FDA cleared the IND for DT-168, the FECD eye-drop candidate. The company expects to begin Phase 1 development in 2024 and is conducting an observational study intended to recruit 200 FECD patients.
- HD and DM1 programs remain in preclinical or discovery development. The company plans to select an HD development candidate and continue evaluating DM1 candidates.
Outlook, risks and contingencies
- Development outlook: The company aims to complete GLP studies for DT-216P2 by year-end 2024 and, subject to regulatory clearance, initiate FA clinical trials in 2025. These are forward-looking targets, not assurances. DT-168 Phase 1 initiation is expected in 2024.
- Financial outlook: Management expects continued losses and increasing expenses as programs advance. The filing provides no revenue or profitability guidance and cautions that the cash runway estimate depends on assumptions that may prove inaccurate.
- Principal risks: Clinical and regulatory uncertainty; potential safety issues, including prior thrombophlebitis; manufacturing and single-source supply dependence; competition, including an approved FA therapy; reliance on third-party research and clinical vendors; and the need for future financing, which could dilute shareholders or constrain development.
- Commitments: The WARF license may require aggregate future regulatory and commercial milestone payments of up to $17.5 million, plus low-single-digit royalties on product sales and other potential fees. The company also has related-party leases with terms ending in 2027.
- Other items: No material litigation or contingent liabilities were reported. Management concluded disclosure controls were effective as of March 31, 2024, and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Progress and timing of DT-216P2 GLP work, a new IND, and the planned 2025 FA trial; assess whether formulation tolerability is demonstrated in humans.
- Whether DT-168 Phase 1 begins in 2024 and what the trial design and initial safety data show.
- Quarterly cash burn, investment balances, and the assumptions behind management’s greater-than-12-month runway estimate.
- Future financing needs and potential dilution, including use of the available shelf registration and ATM program; no ATM shares had been sold as of March 31, 2024.
- Progress in selecting HD and DM1 candidates, and any changes to pipeline priorities or spending.